Efficacy, safety of biosimilar filgrastim similar to that of filgrastim in daily practice
the ONA take:
The clinical effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim for the prevention of chemotherapy-induced (febrile) neutropenia, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the international, prospective, observational, open-label MONITOR-GCSF study, researchers enrolled 1,447 patients with cancer treated with myelosuppressive chemotherapy and receiving prophylaxis with biosimilar filgrastim. Of those, 72.3% received primary prophylaxis and 53.2% initiated prophylaxis between 24 and 72 hours after chemotherapy.
Results showed that 13.2% and 5.9% of patients experienced grade 4 chemotherapy-induced neutropenia and febrile neutropenia, respectively.
Researchers found that 6.1% of patients were hospitalized for (febrile) neutropenia. In regard to safety, 24.7% of patients reported any grade bone pain and 76 patients experienced a total of 148 adverse drug events, of which 4 were serious.
Effectiveness and safety of biosimilar filgrastim (Zarxio) in daily clinical practice are similar to that of the originator filgrastim.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|